Immunotherapy Overtakes Targeted Therapy as First-Line Standard of Care for mRCC – OncLive
OncLive |
Immunotherapy Overtakes Targeted Therapy as First-Line Standard of Care for mRCC
OncLive An extension in overall survival (OS) seen with the combination of nivolumab (Opdivo) and ipilimumab (Yervoy) has completely changed the standard of care for patients with metastatic renal cell carcinoma (mRCC), Thomas Powles MBBS, MRCP, MD, told … |
